StockData
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. (FDMT) income statement

FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3017% below fair value
$10.46−0.33 (-3.06%)

Close on Nov 18, 2026Market cap $755.00MP/E –Yield –

4D Molecular Therapeutics, Inc. financial ratios

See a number that looks wrong?